Erratum: Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene (American Society for Clinical Investigation (2015)125:4 (1739-1751) DOI 10.1172/JCI74692);Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1739-1751

  Knowles, Joshua W ^a   Xie, Weijia ^b   Zhang, Zhongyang ^c   Chennemsetty, Indumathi ^a   Assimes, Themistocles L ^a   Paananen, Jussi ^d   Hansson, Ola ^e   Pankow, James ^f   Goodarzi, Mark O ^g   Carcamo Orive, Ivan ^a   Morris, Andrew P ^h,i   Chen, Yii Der I ^j   Mäkinen, Ville Petteri ^k   Ganna, Andrea ^l   Mahajan, Anubha ⁱ   Guo, Xiuqing ^j   Abbasi, Fahim ^a   Greenawalt, Danielle M ^m   Lum, Pek ^m   Molony, Cliona ^m   Lind, Lars ^l   Lindgren, Cecilia ⁱ   Raffel, Leslie J ^g   Tsao, Philip S ^a   Schadt, Eric E ^c   Rotter, Jerome I ^j   Sinaiko, Alan ⁿ   Reaven, Gerald ^a   Yang, Xia ^k   Hsiung, Chao A ^o   Groop, Leif ^e   Cordell, Heather J ^p   Laakso, Markku ^d   Hao, Ke ^c   Ingelsson, Erik ^i,l   Frayling, Timothy M ^b   Weedon, Michael N ^b   Walker, Mark ^q   Quertermous, Thomas ^a   more..

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF MINNESOTA   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j HARBOR UCLA MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UPPSALA UNIVERSITY   (Sweden)

^m MERCK RESEARCH LABORATORIES   (United States)

ⁿ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^o NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^p NEWCASTLE UNIVERSITY   (United Kingdom)

^q NEWCASTLE UNIVERSITY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN; GLUCOSE; HEMOGLOBIN A1C; HYDRAZINE; INSULIN; ISOPRENALINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN; ISOENZYME; N-ACETYLTRANSFERASE 1; NAT2 PROTEIN, HUMAN;

ADIPOCYTE; ADIPOGENESIS; ADULT; ANIMAL CELL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENDOCRINE FUNCTION TEST; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; 3T3 CELL LINE; ADOLESCENT; ANIMAL; ASIAN CONTINENTAL ANCESTRY GROUP; CAUCASIAN; CHILD; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; EPIDEMIOLOGY; EUROPE; GENE FREQUENCY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HISPANIC; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; KNOCKOUT MOUSE; LIPOLYSIS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; PHYSIOLOGY; POINT MUTATION; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; UNITED STATES; YOUNG ADULT;

3T3-L1 CELLS; ADIPOGENESIS; ADOLESCENT; ADULT; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CORONARY DISEASE; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISOENZYMES; LIPOLYSIS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MUTATION, MISSENSE; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TAIWAN; UNITED STATES; YOUNG ADULT;

EID: 84926364999     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85921     Document Type: Erratum

References (62)

1. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab. 2001;86(8):3574-3578.
2. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab. 1998;83(8):2773-2776.
3. Einhorn D, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237-252.
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
5. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23(2):171-175.
6. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998;16(7):895-906.
7. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-E223.
8. Pei D, Jones CN, Bhargava R, Chen YD, Reaven GM. Evaluation of octreotide to assess insulinmediated glucose disposal by the insulin suppression test. Diabetologia. 1994;37(8):843-845.
9. Knowles JW, et al. Measurement of insulin-mediated glucose uptake: direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp. Metabolism. 2013;62(4):548-553.
10. Bosy-Westphal A, et al. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: the Kiel obesity prevention study. Int J Obes (Lond). 2007;31(5):784-790.
11. Mills GW, et al. Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia. 2004;47(4):732-738.
12. Altshuler D, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26(1):76-80.
13. Ingelsson E, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes. 2010;59(5):1266-1275.
14. Voight BF, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579-589.
15. Dupuis J, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105-116.
16. Rung J, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41(10):1110-1115.
17. Scott RA, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44(9):991-1005.
18. Rasmussen-Torvik LJ, et al. Heritability and genetic correlations of insulin sensitivity measured by the euglycaemic clamp. Diabet Med. 2007;24(11):1286-1289.
19. Goodarzi MO, et al. Insulin sensitivity and insulin clearance are heritable and have strong genetic correlation in Mexican Americans. Obesity. 2014;22(4):1157-1164.
20. Walraven JM, Zang Y, Trent JO, Hein DW. Structure/ function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab. 2008;9(6):471-486.
21. Sim E, Walters K, Boukouvala S. Arylamine N-acetyltransferases: from structure to function. Drug Metab Rev. 2008;40(3):479-510.
22. Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2012;13(1):31-41.
23. Kuznetsov IB, McDuffie M, Moslehi R. A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype. Bioinformatics. 2009;25(9):1185-1186.
24. Prokopenko I, et al. A central role for GRB10 in regulation of islet function in man. PLoS Genet. 2014;10(4):e1004235.
25. Manning AK, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet. 2012;44(6):659-669.
26. Teslovich TM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707-713.
27. Voight BF, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42(7):579-589.
28. Deloukas P, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25-33.
29. Hein DW, Boukouvala S, Grant DM, Minchin RF, Sim E. Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics. 2008;18(4):367-368.
30. Chan KH, et al. Shared molecular pathways and gene networks for cardiovascular disease and type 2 diabetes mellitus in women across diverse ethnicities. Circ Cardiovasc Genet. 2014;7(6):911-919.
31. Sim E, Westwood I, Fullam E. Arylamine N-acetyltransferases. Expert Opin Drug Metab Toxicol. 2007;3(2):169-184.
32. Cornish VA, et al. Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics J. 2003;3(3):169-177.
33. Sugamori KS, et al. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Mol Pharmacol. 2003;64(1):170-179.
34. Sugamori KS, et al. Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice. Cancer Lett. 2012;318(2):206-213.
35. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990;9(3):193-203.
36. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol. 1991;39(2):184-191.
37. Kawamura A, et al. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem Pharmacol. 2005;69(2):347-359.
38. Hein DW, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000;9(1):29-42.
39. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960;2(5197):485-491.
40. Cartwright RA, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet. 1982;2(8303):842-845.
41. Rothman N, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010;42(11):978-984.
42. Suhre K, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477(7362):54-60.
43. Suhre K, et al. A genome-wide association study of metabolic traits in human urine. Nat Genet. 2011;43(6):565-569.
44. Eny KM, et al. GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence. Diabetologia. 2014;57(8):1623-1634.
45. Grant DM, et al. Human acetyltransferase polymorphisms. Mutat Res. 1997;376(1):61-70.
46. Zang Y, Doll MA, Zhao S, States JC, Hein DW. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis. 2007;28(8):1665-1671.
47. Luca F, et al. Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS One. 2008;3(9):e3136.
48. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982;7(5):373-400.
49. Lango Allen H, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature. 2010;467(7317):832-838.
50. Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-948.
51. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010;34(8):816-834.
52. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44(8):955-959.
53. Morris AP, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981-990.
54. Yue P, et al. Apelin decreases lipolysis via G(q), G(i), and AMPK-dependent mechanisms. Endocrinology. 2011;152(1):59-68.
55. Chennamsetty I, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest. 2011;121(9):3724-3734.
56. Blodgett AB, Kothinti RK, Kamyshko I, Petering DH, Kumar S, Tabatabai NM. A fluorescence method for measurement of glucose transport in kidney cells. Diabetes Technol Ther. 2011;13(7):743-751.
57. Chennamsetty I, et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res. 2012;53(11):2405-2412.
58. Yue P, et al. Apelin is necessary for the maintenance of insulin sensitivity. American journal of physiology. Am J Physiol Endocrinol Metab. 2010;298(1):E59-E67.
59. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-909.
60. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190-2191.
61. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes. 1981;30(5):387-392.
62. Soranzo N, et al. Common variants at 10 genomic loci influence hemoglobin A(1) (C) levels via glycemic and nonglycemic pathways. Diabetes. 2010;59(12):3229-3239.